Abstract
Aim. To study the effect of catheter-based sympathetic renal denervation (RDN) by radiofrequency ablation on glucose metabolism in patients with type 2 diabetes and uncontrolled hypertension.Material and methods. Sixty patients were randomly assigned in a 1:1 ratio to the RDN group and the control group. Radiofrequency ablation was performed through the femoral access using a Symplicity Spyral™ renal denervation system (Medtronic, USA).Results. The technical success was 100%. There were no any complications. During the follow-up period, patients in the RDN group showed a significant decrease in the average level of glycated hemoglobin — from 7,9 (6,83-8,35) to 6,85 (6,12-7,10)% (p<0,001) and basal glycemia — from 9,5 (7,17-10,28) to 7,55 (6,43-8,95) mmol/l (p<0,001) with no significant changes in the control group. Changes in glucose levels and the degree of insulin resistance correlated with a decrease in office systolic blood pressure (r=0,36, p=0,005). After 6-month follow-up period in the RDN group, along with a significant decrease in the HOMA-IR by 1,92 (p<0,001), the average high-density lipoprotein cholesterol level also significantly increased by 0,17 mmol/l (p<0,001), and mean triglyceride level decreased by -0,55 mmol/l (p<0,001).Conclusion. The study results confirm the hypothesis of pleiotropic effects of RDN in patients with comorbid pathology associated with central sympathetic nervous system hyperactivity (diabetes, hypertension, dyslipidemia).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.